Overview

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.
Phase:
Phase 1
Details
Lead Sponsor:
Chugai Pharmaceutical
Treatments:
Antibodies, Monoclonal